Novo Nordisk's Saxenda shows promising results - Nordic Life Science – the leading Nordic life science news service
Novo Nordisk Korea issues weight loss data of Saxenda < Pharma < Article - KBR
Novo Nordisk drags competitor to court over Saxenda copies — MedWatch
FDA approves Novo Nordisk Obesity Drug Saxenda • NCK Pharma
Prescription Weight-Loss Medicine | Saxenda® (liraglutide) injection 3mg
Novo Nordisk preps Saxenda sales drive in Latin America after its 'phenomenal' Q1 | Fierce Pharma
Novo Nordisk's new obesity drug hits 8,000-prescription mark in few weeks: Comparing with Saxenda, it took around four years — MedWatch
Positive new trial results for obesity treatment Saxenda in early resp
Saxenda approved in Europe for the treatment of obesity
![Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States](https://photos.prnewswire.com/prnfull/20150421/200096 "Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States")
Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States
Novo Nordisk's Wegovy supply woes were an unexpected boon for Saxenda
Can Novo Nordisk's pipeline transform obesity treatment? | pharmaphorum
Novo Nordisk readies new obesity treatment after Saxenda < Pharma < Article - KBR
Novo Nordisk 2018: Struggling against the tide – PharmaLive
Saxenda®
Results about Novo's Saxenda
Saxenda (liraglutide) for the Treatment of Obesity - Clinical Trials Arena
Saxenda: profiling the first NHS weight loss drug for a decade - Pharmaceutical Technology
